Leukemia & Lymphoma Society
15
26M
14
0.19
2
0.07
6
- Stages of investment
- Areas of investment
Summary
In 1944 was created Leukemia & Lymphoma Society, which is appeared as Corporate Investor. The venture was found in North America in United States. The leading representative office of defined Corporate Investor is situated in the White Plains.
The usual cause for the fund is to invest in rounds with 1 partaker. Despite the Leukemia & Lymphoma Society, startups are often financed by Sutter Hill Ventures, National Institutes of Health, Lightspeed Venture Partners. In the next rounds fund is usually obtained by GlaxoSmithKline, Celgene.
Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Health Care, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has specific favorite in a number of founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline OncoPep, Epizyme
The increased amount of exits for fund were in 2013. The top activity for fund was in 2019. The common things for fund are deals in the range of 5 - 10 millions dollars. The fund is generally included in less than 2 deals every year.
Investments analytics
Analytics
- Total investments
- 15
- Lead investments
- 2
- Exits
- 6
- Rounds per year
- 0.19
- Follow on index
- 0.07
- Investments by industry
- Biotechnology (14)
- Health Care (9)
- Medical (7)
- Therapeutics (6)
- Pharmaceutical (6) Show 6 more
- Investments by region
-
- United States (10)
- France (1)
- Finland (2)
- Switzerland (1)
- Poland (1)
- Peak activity year
- 2021
- Number of Unicorns
- 2
- Number of Decacorns
- 2
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 19
- Avg. valuation at time of investment
- 493M
- Group Appearance index
- 0.27
- Avg. company exit year
- 9
- Avg. multiplicator
- 7.53
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Constellation Pharmaceuticals | 01 Sep 2012 | Biotechnology, Genetics, Medical, Pharmaceutical | Late Stage Venture | United States, Massachusetts, Cambridge |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.